Literature DB >> 3216213

Multimodality evoked potentials in HTLV-I associated myelopathy.

R Kakigi1, H Shibasaki, Y Kuroda, C Endo, K Oda, A Ikeda, K Hashimoto.   

Abstract

Multimodality evoked potentials (EPs) consisting of somatosensory EPs (SEPs), visual EPs (VEPs) and brainstem auditory EPs (BAEPs) were studied in 16 cases with HTLV-I associated myelopathy (HAM). Median nerve SEPs were normal in all cases. In posterior tibial nerve SEPs, the potential recorded at the 12th thoracic spinal process was normal in every case but cortical components were significantly prolonged in 10 cases, although five of these showed no sensory impairment. BAEPs were normal in every case whose hearing was intact, but VEPs were abnormal in two cases whose visual acuities were normal. The present results in HAM indicate predominant lesion in the thoracic cord, and might also suggest some subclinical lesion in the visual pathway.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3216213      PMCID: PMC1033123          DOI: 10.1136/jnnp.51.8.1094

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

1.  The effect of aging on somatosensory evoked potentials following stimulation of the posterior tibial nerve in man.

Authors:  R Kakigi
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1987-07

2.  Clinical electrophysiologic studies of HTLV-I-associated myelopathy.

Authors:  K Arimura; R Rosales; M Osame; A Igata
Journal:  Arch Neurol       Date:  1987-06

3.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

Review 4.  Pattern shift visual, brainstem auditory, and short-latency somatosensory evoked potentials in multiple sclerosis.

Authors:  K H Chiappa
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

5.  Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical and seroepidemiological study of 25 cases.

Authors:  J C Vernant; L Maurs; A Gessain; F Barin; O Gout; J M Delaporte; K Sanhadji; G Buisson; G de-Thé
Journal:  Ann Neurol       Date:  1987-02       Impact factor: 10.422

6.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

7.  Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells.

Authors:  M Osame; M Matsumoto; K Usuku; S Izumo; N Ijichi; H Amitani; M Tara; A Igata
Journal:  Ann Neurol       Date:  1987-02       Impact factor: 10.422

8.  Antibody to human T-lymphotropic virus type 1 in West-Indian-born UK residents with spastic paraparesis.

Authors:  M Newton; K Cruickshank; D Miller; A Dalgleish; P Rudge; S Clayden; I Moseley
Journal:  Lancet       Date:  1987-02-21       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.